{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T03:28:33Z","timestamp":1776742113083,"version":"3.51.2"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,11]],"date-time":"2022-10-11T00:00:00Z","timestamp":1665446400000},"content-version":"vor","delay-in-days":283,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.ctarc.2022.100648","type":"journal-article","created":{"date-parts":[[2022,10,13]],"date-time":"2022-10-13T09:40:28Z","timestamp":1665654028000},"page":"100648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies"],"prefix":"10.1016","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8834-1296","authenticated-orcid":false,"given":"Adam","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Eccles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anushri","family":"Chitkara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Dal\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nebibe","family":"Varol","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100648_bib0001","year":"2022","journal-title":"Cancer Facts & Figures 2022"},{"key":"10.1016\/j.ctarc.2022.100648_bib0002","doi-asserted-by":"crossref","unstructured":"Siegel, R.L., et\u00a0al., Cancer statistics, 2022. CA: a cancer journal for clinicians, 2022.","DOI":"10.3322\/caac.21708"},{"key":"10.1016\/j.ctarc.2022.100648_bib0003","year":"2021","journal-title":"Lung Cancer Survival Rates"},{"key":"10.1016\/j.ctarc.2022.100648_bib0004","series-title":"SEER Cancer Statistics Review (CSR), 1975-2017","first-page":"2020","author":"Howlader","year":"2017"},{"key":"10.1016\/j.ctarc.2022.100648_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00881-7","article-title":"Emerging therapeutic agents for advanced non-small cell lung cancer","volume":"13","author":"Chen","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100648_bib0006","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1634\/theoncologist.12-6-713","article-title":"FDA drug approval summary: Bevacizumab (Avastin\u00ae) plus carboplatin and paclitaxel as first-line treatment of advanced\/metastatic recurrent nonsquamous non-small cell lung cancer","volume":"12","author":"Cohen","year":"2007","journal-title":"The Oncologist"},{"key":"10.1016\/j.ctarc.2022.100648_bib0007","unstructured":"U.S. Food and Drug Administration. FDA approves osimertinib for first-line treatment of metastatic NSCLC with most common EGFR mutations. 2018 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-osimertinib-first-line-treatment-metastatic-nsclc-most-common-egfr-mutations."},{"key":"10.1016\/j.ctarc.2022.100648_bib0008","unstructured":"U.S. Food and Drug Administration. FDA broadens afatinib indication to previously untreated, metastatic NSCLC with other non-resistant EGFR mutations. 2018 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-broadens-afatinib-indication-previously-untreated-metastatic-nsclc-other-non-resistant-egfr."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100648_bib0009","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1634\/theoncologist.10-7-461","article-title":"FDA drug approval summary: erlotinib (Tarceva\u00ae) tablets","volume":"10","author":"Cohen","year":"2005","journal-title":"The Oncologist"},{"key":"10.1016\/j.ctarc.2022.100648_bib0010","unstructured":"U.S. Food and Drug Administration. FDA approves nivolumab plus ipilimumab for first-line mNSCLC (PD-L1 tumor expression \u22651%). 2020 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-nivolumab-plus-ipilimumab-first-line-mnsclc-pd-l1-tumor-expression-1."},{"key":"10.1016\/j.ctarc.2022.100648_bib0011","unstructured":"U.S. Food and Drug Administration. FDA expands pembrolizumab indication for first-line treatment of NSCLC (TPS \u22651%). 2019 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/fda-expands-pembrolizumab-indication-first-line-treatment-nsclc-tps-1."},{"key":"10.1016\/j.ctarc.2022.100648_bib0012","unstructured":"U.S. Food and Drug Administration. FDA approves cemiplimab-rwlc for non-small cell lung cancer with high PD-L1 expression. 2021 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/drug-approvals-and-databases\/fda-approves-cemiplimab-rwlc-non-small-cell-lung-cancer-high-pd-l1-expression."},{"key":"10.1016\/j.ctarc.2022.100648_bib0013","unstructured":"U.S. Food and Drug Administration. FDA approves durvalumab after chemoradiation for unresectable stage III NSCLC. 2018 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-durvalumab-after-chemoradiation-unresectable-stage-iii-nsclc."},{"key":"10.1016\/j.ctarc.2022.100648_bib0014","unstructured":"U.S. Food and Drug Administration. FDA approves atezolizumab for first-line treatment of metastatic NSCLC with high PD-L1 expression. 2020 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-atezolizumab-first-line-treatment-metastatic-nsclc-high-pd-l1-expression."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100648_bib0015","doi-asserted-by":"crossref","first-page":"254","DOI":"10.6004\/jnccn.2021.0013","article-title":"NCCN guidelines insights: non\u2013small cell lung cancer, version 2.2021: featured updates to the NCCN guidelines","volume":"19","author":"Ettinger","year":"2021","journal-title":"J. Nat. Comprehensive Cancer Network"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100648_bib0016","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1245\/s10434-010-0985-4","article-title":"The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM","volume":"17","author":"Edge","year":"2010","journal-title":"Ann. Surgical Oncol."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100648_bib0017","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/JTO.0b013e31819e7814","article-title":"The 7th Edition of TNM in Lung Cancer: what now?","volume":"4","author":"Goldstraw","year":"2009","journal-title":"J. Thoracic Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100648_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS medicine"},{"key":"10.1016\/j.ctarc.2022.100648_bib0019","first-page":"355","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","author":"Sterne","year":"2016","journal-title":"bmj"},{"key":"10.1016\/j.ctarc.2022.100648_bib0020","year":"2021","journal-title":"Risk of Bias In Non-Randomized Stud. - of Interventions (ROBINS-I)"},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100648_bib0021","doi-asserted-by":"crossref","first-page":"e19295","DOI":"10.1200\/JCO.2020.38.15_suppl.e19295","article-title":"Comparison of characteristics and outcomes among veterans receiving first-line immunotherapy versus chemotherapy for stage IV non-small cell lung cancer","volume":"38","author":"Williams","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.ctarc.2022.100648_bib0022","doi-asserted-by":"crossref","first-page":"e21208","DOI":"10.1200\/JCO.2018.36.15_suppl.e21208","article-title":"Retrospective analysis of clinical outcome of EGFR mutated patients in a county hospital","volume":"36","author":"Rai","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"7","key":"10.1016\/j.ctarc.2022.100648_bib0023","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.jtho.2016.03.023","article-title":"Lung cancer in the very young: treatment and survival in the national cancer data base","volume":"11","author":"Arnold","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2022.100648_bib0024","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ijrobp.2019.01.096","article-title":"Real-world performance of blood-based proteomic profiling in frontline immunotherapy treatment in advanced stage NSCLC","volume":"104","author":"Rich","year":"2019","journal-title":"Int. J. Radiation Oncol. \u2022 Biol. \u2022 Phys."},{"issue":"6","key":"10.1016\/j.ctarc.2022.100648_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.7205","article-title":"Association of programmed cell death ligand 1 expression status with receipt of immune checkpoint inhibitors in patients with advanced non\u2013small cell lung cancer","volume":"3","author":"Leapman","year":"2020","journal-title":"JAMA Network Open"},{"issue":"2","key":"10.1016\/j.ctarc.2022.100648_bib0026","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.lungcan.2014.11.002","article-title":"Real-world treatment patterns and costs in a US Medicare population with metastatic squamous non-small cell lung cancer","volume":"87","author":"Davis","year":"2015","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.ctarc.2022.100648_bib0027","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178420","article-title":"Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting","volume":"12","author":"Abernethy","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ctarc.2022.100648_bib0028","article-title":"A real world observational assessment of the impact of immunotherapy on the treatment of advanced non-small cell lung cancer (NSCLC)","author":"El Ferjani","year":"2019","journal-title":"NCCN 2019"},{"issue":"10","key":"10.1016\/j.ctarc.2022.100648_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtho.2018.08.1651","article-title":"Computing the impact of immunotherapy on the non-small cell lung cancer (nsclc) therapeutic landscape: P3. 01-91","volume":"13","author":"Vaghani","year":"2018","journal-title":"J. Thoracic Oncol."},{"key":"10.1016\/j.ctarc.2022.100648_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1186\/s12913-014-0555-8","article-title":"Comparison of demographics, treatment patterns, health care utilization, and costs among elderly patients with extensive-stage small cell and metastatic non-small cell lung cancers","volume":"14","author":"Karve","year":"2014","journal-title":"BMC Health Services Res."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100648_bib0031","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2217\/lmt.13.20","article-title":"Treatment patterns and healthcare costs among patients with advanced non-small-cell lung cancer","volume":"2","author":"Henk","year":"2013","journal-title":"Lung Cancer Manag."},{"key":"10.1016\/j.ctarc.2022.100648_bib0032","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1016\/j.jval.2020.04.1796","article-title":"PCN338 metastatic non-small cell lung CANCER (NSCLC) patient characteristics and treatment patterns: a comparison between health insurance claims and electronic health records (EHRS)","volume":"23","author":"Choi","year":"2020","journal-title":"Value in Health"},{"key":"10.1016\/j.ctarc.2022.100648_bib0033","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/j.jval.2020.04.1525","article-title":"PCN19 patient characteristics and first line treatments among medicare patients with metastatic non-small cell lung cancer (MNSCLC)","volume":"23","author":"Ejzykowicz","year":"2020","journal-title":"Value in Health"},{"issue":"4","key":"10.1016\/j.ctarc.2022.100648_bib0034","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.cllc.2018.02.002","article-title":"Treatment patterns and clinical outcomes among metastatic non-small-cell lung cancer patients treated in the community practice setting","volume":"19","author":"Nadler","year":"2018","journal-title":"Clin. Lung Cancer"},{"key":"10.1016\/j.ctarc.2022.100648_bib0035","doi-asserted-by":"crossref","first-page":"xi27","DOI":"10.1093\/annonc\/mdz449.030","article-title":"Real-world data analysis of PD-L1 expression and overall survival (OS) in advanced non-small cell lung cancer (aNSCLC)","volume":"30","author":"Staib","year":"2019","journal-title":"Ann. Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2022.100648_bib0036","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s12325-018-0811-0","article-title":"Treatment patterns by EGFR mutation status in non-small cell lung cancer patients in the USA: a retrospective database analysis","volume":"35","author":"Aguilar","year":"2018","journal-title":"Adv. Ther."},{"issue":"2","key":"10.1016\/j.ctarc.2022.100648_bib0037","doi-asserted-by":"crossref","first-page":"195","DOI":"10.18553\/jmcp.2017.23.2.195","article-title":"Treatment patterns and overall survival associated with first-line systemic therapy for patients with advanced non-small cell lung cancer","volume":"23","author":"Spence","year":"2017","journal-title":"J. Managed Care & Specialty Pharmacy"},{"issue":"30","key":"10.1016\/j.ctarc.2022.100648_bib0038","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.2217\/fon-2019-0348","article-title":"Treatment patterns and overall survival in metastatic non-small-cell lung cancer in a real-world, US setting","volume":"15","author":"Simeone","year":"2019","journal-title":"Future Oncol."},{"issue":"11","key":"10.1016\/j.ctarc.2022.100648_bib0039","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1634\/theoncologist.2017-0078","article-title":"FDA approval summary: pembrolizumab for treatment of metastatic non-small cell lung cancer: first-line therapy and beyond","volume":"22","author":"Pai-Scherf","year":"2017","journal-title":"The Oncologist"},{"key":"10.1016\/j.ctarc.2022.100648_bib0040","unstructured":"U.S. Food and Drug Administration. FDA grants regular approval for pembrolizumab in combination with chemotherapy for first-line treatment of metastatic nonsquamous NSCLC. 2018 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-regular-approval-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic."},{"key":"10.1016\/j.ctarc.2022.100648_bib0041","unstructured":"U.S. Food and Drug Administration. FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC. 2018 [cited 2021; Available from: https:\/\/www.fda.gov\/drugs\/fda-approves-pembrolizumab-combination-chemotherapy-first-line-treatment-metastatic-squamous-nsclc."},{"issue":"3","key":"10.1016\/j.ctarc.2022.100648_bib0042","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkz020","article-title":"First-line systemic treatments for stage IV non-small cell lung cancer in California: patterns of care and outcomes in a real-world setting","volume":"3","author":"Maguire","year":"2019","journal-title":"JNCI Cancer Spectrum"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:37:21Z","timestamp":1762843041000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222001393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":42,"alternative-id":["S2468294222001393"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100648","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment patterns for advanced non-small cell lung cancer in the US: A systematic review of observational studies","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100648"}}